France Psoriasis Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Psoriasis Drugs market is growing globally due to the rise in the prevalence of chronic diseases globally, growing awareness and diagnosis about the disease, advancements in biologic therapies like TNF inhibitors, IL-17 inhibitors and IL-23 inhibitors, pipeline development including small molecules and biologics, patient support programs and patient advocacy groups, increase in collaborations among pharmaceutical companies and research organizations, surge in government initiatives and development in technology. Eli Lilly & Company, Pfizer Inc., Janssen Global Services LLC, Celgene Corporation, Takeda Pharmaceutical Company Limited, Novartis International AG, Amgen Inc., Biogen Inc., Abbvie Inc., AstraZeneca, Boeringer Ingelheim International GmbH, Biogen, Johnson & Johnson Services Inc., Merck & Co. Inc., Sun Pharmaceuticals Industries Ltd., Stiefel Laboratories, UCB S.A., LEO Pharma, Cipla Inc., Rowan Bioceuticals, Glenmark Pharmaceuticals, and Win-Medicare Pvt. Ltd., are the key global market players in psoriasis drug market.
France Psoriasis Drugs Market is valued at around $735.7 Mn in 2022 and is projected to reach $1292.7 Mn by 2030, exhibiting a CAGR of 7.3% during the forecast period 2023-2030.
Psoriasis is a chronic autoimmune condition that mostly affects the skin although it can affect other regions of the body as well. The rapid accumulation of skin cells that results in the development of thick, red patches, scales, and plaques is one of its defining characteristics. A hyperactive immune system that unintentionally kills healthy skin cells is the root cause of psoriasis. Although the precise etiology of psoriasis is unknown, it is thought to be a result of a confluence of immune system, environmental, and genetic factors. Other symptoms may include itching, burning, and soreness in the affected areas. Psoriasis can also lead to joint inflammation, known as psoriatic arthritis, causing pain, stiffness, and swelling in the joints.
Topical treatments include corticosteroids, vitamin D analogs (such as calcipotriene), retinoids, salicylic acid, and coal tar, all of which are administered directly to the skin, and this helps to reduce the symptoms of the disease. Systemic Medications for moderate to severe treatments include Biologic therapies which include drugs like tumor necrosis factor (TNF) inhibitors (e.g., adalimumab, etanercept), interleukin (IL)-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., ustekinumab, guselkumab), oral retinoids, Methotrexate, cyclosporine and phototherapy which includes UVA therapy and UVB therapy. Eli Lilly & Company, Pfizer Inc., Janssen Global Services LLC, Celgene Corporation, Takeda Pharmaceutical Company Limited, Novartis International AG, Amgen Inc., Biogen Inc., Abbvie Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Biogen, Johnson & Johnson Services Inc., Merck & Co. Inc., Sun Pharmaceuticals Industries Ltd., Stiefel Laboratories, UCB S.A., LEO Pharma, Cipla Inc., Rowan Bioceuticals, Glenmark Pharmaceuticals, and Win-Medicare Pvt. Ltd., are the key global market players in psoriasis drug market.
Market Growth Drivers
Increase in the prevalence of chronic diseases globally, growing awareness and diagnosis about the disease, advancements in biologic therapies like TNF inhibitors, IL-17 inhibitors and IL-23 inhibitors, pipeline development including small molecules and biologics, patient support programs and patient advocacy groups, increase in collaborations among pharmaceutical companies and research organizations, surge in government initiatives and development in technology. All these factors act as market growth drivers.
Market Restraints
High Cost of Biologic Therapies, Stringent Regulatory Requirements, Side Effects, and Safety Concerns including increased risk of infections, injection-site reactions, and long-term safety concerns, Limited Insurance Coverage, and reimbursement policies act as market growth restraints.
Key Players
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Type of Treatment
By Mechanism of Action
By Route of Administration
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.